Methods for Modulating Inflammatory Responses

Abstract

The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.

1 .- 18 . (canceled) 
     
     
         19 . A method for the suppression or amelioration of an inflammatory response in a subject having an inflammatory disease of the integument the method comprising the step of administering to the subject about 0.1-1000 μg/cm 2  applied area an effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) such that the inflammatory response is suppressed or ameliorated. 
     
     
         20 . A method for reducing inflammation associated with the development of an inflammatory response in a subject having an inflammatory disease of the integument the method comprising the step of administering to the subject about 0.1-1000 μg/cm 2  applied area an effective amount of ACCS such that inflammation associated with the development of an inflammatory response is reduced. 
     
     
         21 . The method of  claim 19  or  20  wherein the inflammatory disease of the integument is selected from the group consisting of psoriasis and atopic dermatitis. 
     
     
         22 . The method of  claim 19  or  20  wherein the ACCS is co-administered with one or more active agents. 
     
     
         23 . The method of  claim 22  wherein the one or more active agents is selected from the group consisting of a corticosteroid, cyclosporine, tacrolimus, sirolimus, methotrexate, azathiopine, mercatopurine, a cytotoxic antibiotic, a polyclonal antibody, a monoclonal antibody, an interferon, opioid, a TNF binding protein, mycophenolate, FTY720 and other cells types. 
     
     
         24 . The method of  claim 23  wherein the monoclonal antibody is selected from the group consisting of an anti-T-cell receptor (CD23) and an anti-IL2 receptor (CD25) antibody. 
     
     
         25 . A method for the suppression or amelioration of an inflammatory response in a subject having an inflammatory bowel disease the method comprising the step of enterally administering to the subject an effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) such that the inflammatory response is suppressed or ameliorated. 
     
     
         26 . A method for reducing inflammation associated with the development of an inflammatory response in a subject having an inflammatory bowel disease the method comprising the step of enterally administering to the an effective amount of ACCS such that inflammation associated with the development of an inflammatory response is reduced. 
     
     
         27 . The method of  claim 25  or  26  wherein the inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn's disease. 
     
     
         28 . The method of  claim 25  or  26  wherein the ACCS is co-administered with one or more active agents. 
     
     
         29 . The method of  claim 28  wherein the one or more active agents is selected from the group consisting of a corticosteroid, cyclosporine, tacrolimus, sirolimus, methotrexate, azathiopine, mercatopurine, a cytotoxic antibiotic, a polyclonal antibody, a monoclonal antibody, an interferon, opioid, a TNF binding protein, mycophenolate, FTY720 and other cells types. 
     
     
         30 . The method of  claim 29  wherein the monoclonal antibody is selected from the group consisting of an anti-T-cell receptor (CD23) and an anti-IL2 receptor (CD25) antibody.